Investor Relations

 
 

Welcome to Lexaria Bioscience (Nasdaq: LEXX)

Videos

What is DehydraTECH?

Lexaria's R&D Programs

Latest Financial Results

Q2 2022

Quarter Ended Feb 28, 2022

Latest Annual Filing

For Fiscal Year Ending Aug 31, 2021

Company Overview

Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 24 patents granted and over 50 patents pending worldwide.

Investor Contact Information

Company

Lexaria Bioscience Corp.
740 McCurdy Road
Suite 100
Kelowna, BC V1X 2P7
Canada

Investor Relations

IR contact
T: 250-765-6424 ext. 202
IR@lexariabioscience.com

Transfer Agent

Computershare Investor Services Inc.
T: 800-564-6253
www.computershare.com

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.